{
    "clinical_study": {
        "@rank": "16625", 
        "arm_group": [
            {
                "arm_group_label": "SB4 (proposed biosimilar to etanercept)", 
                "arm_group_type": "Experimental", 
                "description": "SB4 50 mg/week via subcutaneous injection"
            }, 
            {
                "arm_group_label": "Enbrel (etanercept)", 
                "arm_group_type": "Active Comparator", 
                "description": "Enbrel 50 mg/week via subcutaneous injection"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate\n      the efficacy, safety, pharmacokinetics and immunogenicity of SB4 compared to Enbrel in\n      subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX)\n      therapy."
        }, 
        "brief_title": "A Study Comparing SB4 to Enbrel\u00ae in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy", 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6\n             months but not exceeding 15 years prior to Screening\n\n          -  Have moderate to severe active disease despite MTX therapy defined as having more\n             than or equal to six swollen joints and more than or equal to six tender joints and\n             either erythrocyte sedimentation rate (ESR, Westergren) \u2265 28 mm/h or serum C-reactive\n             protein \u2265 1.0 mg/dL\n\n          -  Must have been treated with MTX for at least 6 months prior to Randomisation and on a\n             stable dose of MTX 10-25 mg/week given at least 4 weeks prior to Screening\n\n          -  Female subjects who are not pregnant or nursing at Screening and who are not planning\n             to become pregnant from Screening until 2 months after the last dose of\n             investigational product\n\n        Exclusion Criteria:\n\n          -  Have been treated previously with any biological agents including any tumour necrosis\n             factor inhibitor\n\n          -  Have a known hypersensitivity to human immunoglobulin proteins or other components of\n             Enbrel or SB4\n\n          -  Have a positive serological test for hepatitis B or hepatitis C or have a known\n             history of infection with human immunodeficiency virus\n\n          -  Have a current diagnosis of active tuberculosis\n\n          -  Have had a serious infection or have been treated with intravenous antibiotics for an\n             infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.\n\n          -  Have any of the following conditions\n\n               1. Other inflammatory or rheumatic diseases.\n\n               2. History of any malignancy within the previous 5 years prior to Screening\n\n               3. History of lymphoproliferative disease including lymphoma.\n\n               4. History of congestive heart failure\n\n               5. Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).\n\n               6. History of demyelinating disorders."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "498", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895309", 
            "org_study_id": "SB4-G31-RA"
        }, 
        "intervention": [
            {
                "arm_group_label": "Enbrel (etanercept)", 
                "intervention_name": "Enbrel (etanercept)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SB4 (proposed biosimilar to etanercept)", 
                "intervention_name": "SB4 (proposed biosimilar to etanercept)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "TNFR-Fc fusion protein"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Rheumatoid Arthritis", 
            "Etanercept", 
            "Biosimilar"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kielce", 
                        "country": "Poland"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "state": "Hampshire"
                    }, 
                    "name": "Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Poland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel\u00ae in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy", 
        "overall_official": {
            "affiliation": "Charles University, Czech Republic", 
            "last_name": "Jiri Vencovsky, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "American College of Rheumatology 20% response criteria (ACR20)", 
            "safety_issue": "No", 
            "time_frame": "Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "ACR20", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "American College of Rheumatology 50% response criteria (ACR50)", 
                "safety_issue": "No", 
                "time_frame": "Week 24, Week 52"
            }, 
            {
                "measure": "Disease activity score based on a 28 joint count (DAS28)", 
                "safety_issue": "No", 
                "time_frame": "Week 24, Week 52"
            }
        ], 
        "source": "Samsung Bioepis Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Bioepis Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}